Genocea Biosciences (NASDAQ:GNCA) commences a Phase 2 dose optimization trial for GEN-003, its immunotherapy candidate for herpes simplex-type 2 (HSV-2). The 300-patient 17-site study will evaluate six combinations of two antigen doses (30 or 60 mcg) with each of three adjuvant doses alongside a placebo. All subjects will receive three doses of GEN-003 or placebo at 21-day intervals.
The primary endpoint is the change in viral shedding rate from baseline.
The company expects to announce interim results in mid-2015.